
- /
- Supported exchanges
- / US
- / HALO.NASDAQ
Halozyme Therapeutics Inc (HALO NASDAQ) stock market data APIs
Halozyme Therapeutics Inc Financial Data Overview
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Halozyme Therapeutics Inc data using free add-ons & libraries
Get Halozyme Therapeutics Inc Fundamental Data
Halozyme Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 084 M
- EBITDA: 673 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 0.972
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Halozyme Therapeutics Inc News

Halozyme Therapeutics added to Russell 1000 index
* Halozyme Therapeutics (NASDAQ:HALO [https://seekingalpha.com/symbol/HALO]) on Monday said it has been added to the U.S. large-cap Russell 1000 Index, effective after market close on June 27, as p...


Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market...

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Achieving those goals is made easier with the Zacks Style Scores, a unique set of ...

Merck's SWOT analysis: stock faces keytruda patent cliff, pipeline potential
Merck (NSE:PROR) & Co., Inc. (NYSE:MRK), a global pharmaceutical giant, finds itself at a critical juncture as it navigates the challenges of patent expirations and market uncertainties while leverag...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.